Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example

Adis Journal Podcasts

Content provided by Adis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Adis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

6M ago 18:36

MP3•Episode home

Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL).

CAR T-cell therapy is effective in the treatment of patients with DLBCL, even those with high-grade disease. However, it has a unique safety profile, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and robust management of these events are important to maximize benefits.

This vodcast audio is published open access in Oncology and Therapy as a vodcast article with visual elements and is fully citeable. You can access the original published vodcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00319-x. All conflicts of interest can be found online.

This vodcast audio is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

87 episodes

#Science #Fitness #Biology #Medicine #Clinicalpractice #Diabetes #Expertopinion #Healthcare #Oncology #Pulmonary #Research #Adi #Podcasting Education #Patient